Targets › CLN3
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Sep 2029.
Mediates microtubule-dependent, anterograde transport connecting the Golgi network, endosomes, autophagosomes, lysosomes and plasma membrane, and participates in several cellular processes such as regulation of lysosomal pH, lysosome protein degradation, receptor-mediated endocytosis, autophagy, transport of proteins and lipids from the TGN, apoptosis and synaptic transmission. Facilitates the proteins transport…. (UniProt, Q13286)
Open in Phaseline: the race on CLN3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Neela Therapeutics | CLN-301 Intrathecal AAV9 gene therapy for CLN3 replacement | CLN3 | Phase 1 | CLN3 | Sep 2029 |
CLN3 (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.